A previous proteomics analysis reported that S100A9 protein was detected in 44% of urine samples, but not in plasma, of pancreatic cancer patients 6, which indicates that urine proteomics might provide tumor-specific biomarkers for pancreatic cancer. This evidence concerns the gene S100A9 and familial pancreatic carcinoma.